Open Menu Close Menu

Education leading to a clear understanding of the appropriate use of biosimilars and other emerging concerns is critical for US physicians and pharmacists preparing for their use in clinical practice. The intent of this CGA is to support educational programs that seek to improve clinician knowledge and competence in the use of biosimilars in the US across multiple therapeutic areas.